ABVC BioPharma, Inc.
ABVC
$0.911
$0.0354.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.60K | 380.00K | 117.10K | 1.20K | 152.40K |
| Total Other Revenue | -11.60K | 9.30K | -- | -- | -150.30K |
| Total Revenue | 2.00K | 389.30K | 117.10K | 1.20K | 2.20K |
| Cost of Revenue | 0.00 | 300.00 | 200.00 | 300.00 | 139.20K |
| Gross Profit | 2.00K | 389.00K | 117.00K | 900.00 | -137.00K |
| SG&A Expenses | 304.10K | 301.20K | 1.05M | 3.38M | 302.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 45.50K | -16.90K | -- | -- | -1.20K |
| Total Operating Expenses | 381.70K | 322.50K | 1.09M | 3.45M | 512.80K |
| Operating Income | -379.70K | 66.80K | -976.60K | -3.44M | -510.70K |
| Income Before Tax | 128.90K | -133.90K | -1.38M | -3.98M | -525.00K |
| Income Tax Expenses | 0.00 | 400.00 | -110.90K | -- | 175.30K |
| Earnings from Continuing Operations | 128.90K | -134.30K | -1.27M | -3.98M | -700.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.40K | -52.30K | 260.00K | 48.00K | 317.00K |
| Net Income | 229.30K | -186.60K | -1.01M | -3.93M | -383.30K |
| EBIT | -379.70K | 66.80K | -976.60K | -3.44M | -510.70K |
| EBITDA | -369.30K | 73.80K | -963.30K | -3.44M | -503.10K |
| EPS Basic | 0.02 | -0.02 | -0.09 | -0.40 | -0.06 |
| Normalized Basic EPS | 0.02 | -0.01 | -0.05 | -0.25 | 0.02 |
| EPS Diluted | 0.02 | -0.02 | -0.09 | -0.40 | -0.06 |
| Normalized Diluted EPS | 0.02 | -0.01 | -0.05 | -0.25 | 0.02 |
| Average Basic Shares Outstanding | 13.20M | 12.41M | 11.32M | 9.74M | 6.68M |
| Average Diluted Shares Outstanding | 13.20M | 12.41M | 11.32M | 9.74M | 6.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |